Can The UK Remain A First Launch Market?
Uncertainty, Modifiers and Discounts Key To NICE Methods Update
More pollical support from the National Health Service and health ministers is needed to ensure the UK’s future as a desirable launch market.
You may also be interested in...
The cancer drug is also to undergo an accelerated assessment by the European Medicines Agency.
Proposals extend the health technology appraisal body's focus beyond final guidance to support for early development and real world performance.
Health technology assessment body NICE wants Kite to collect more evidence to prove that Tecartus can cure relapsed or refractory mantle cell lymphoma. But in the meantime, it says the CAR-T therapy should be made available on the National Health Service, making UK patients among the first in the world to be offered access to the treatment.